Shelby Kinsey lives with a rare, fast-progressing form of ALS — but she has to spend her precious time fighting for insurance ...
In a rare move, the U.S. agency behind Medicare is warning insurers who provide Medicare Advantage plans that they can’t ...
The Centers for Medicare & Medicaid Services has directed private insurers providing Medicare Advantage plans to cover Biogen ...
Corcept Therapeutics said on Wednesday its experimental drug failed to meet the main goal of a mid-stage trial in patients ...
Corcept Therapeutics Incorporated CORT announced data from the phase II DAZALS study evaluating its selective cortisol ...
Corcept Therapeutics’ selective cortisol modulator failed to slow the progress of amyotrophic lateral sclerosis (ALS) in a ...
When Rita Hunter first asked to meet with me, I had no idea she had been diagnosed with Amyotrophic Lateral Sclerosis (ALS) ...
Amyotrophic lateral sclerosis (ALS) is a rare neurological disorder that affects specific nerve cells in the spinal cord known as motor neurons. Symptoms involve issues with swallowing and speech ...
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe e ...
The FDA asked for additional Neurofilament Light (“NfL”) data from the company's three Expanded Access Protocols to support earlier ...
End-of-life health care service use differed between decedents with neurodegenerative diseases and those with pancreatic or brain cancer.
The global amyotrophic lateral sclerosis treatment market size was US$ 637.2 million in 2021. The global amyotrophic lateral sclerosis treatment market is forecast to grow to US$ 918 million by 2030, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback